STOCK TITAN
  1. Home
  2. News
  3. TERN

Terns Pharmaceuticals Inc - TERN STOCK NEWS

Welcome to our dedicated news page for Terns Pharmaceuticals (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Terns Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Terns Pharmaceuticals's position in the market.

News
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
Rhea-AI Summary
Terns Pharmaceuticals, Inc. appoints Melita Sun Jung as chief business officer, bringing over 20 years of experience in the life sciences industry. With a focus on driving valuable partnerships and strategic decisions, her expertise will be instrumental in propelling Terns' oncology and metabolic pipeline programs to mid- and late-stage development. Ms. Jung's track record includes successful collaborations and licensing deals, making her a valuable addition to Terns' leadership team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
management
-
News
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
Rhea-AI Summary
Terns Pharmaceuticals, Inc. reports positive financial results and pipeline updates for 2023. Interim data from Phase 1 trials of TERN-701 and TERN-601 expected in the second half of 2024. Cash position of $263 million to support operations into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.3%
Tags
earnings
-
News
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
Rhea-AI Summary
Terns Pharmaceuticals, Inc. receives Orphan Drug Designation from the FDA for TERN-701, a potential treatment for chronic myeloid leukemia. The drug is an allosteric BCR-ABL tyrosine kinase inhibitor in Phase 1 clinical development, with promising interim data expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.04%
Tags
clinical trial
News
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Rhea-AI Summary
Terns Pharmaceuticals, Inc. granted an equity inducement award to a new employee under the Inducement Plan, with options to purchase 45,000 shares of Terns common stock at an exercise price of $7.31 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
none
-
News
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
Rhea-AI Summary
Terns Pharmaceuticals, Inc. announced participation in upcoming investor conferences in March to discuss their small-molecule product candidates for serious diseases like oncology and obesity. The events include TD Cowen 44th Annual Health Care Conference and Inaugural BMO Obesity Summit, with live webcasts available on the company's investor relations page.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.26%
Tags
conferences
-
News
Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)
Rhea-AI Summary
Terns Pharmaceuticals, Inc. announced the granting of equity inducement awards to its new CEO, Amy Burroughs, under the 2022 Employment Inducement Award Plan. The awards include an option to purchase 1,250,000 shares of Terns common stock and a restricted stock unit award representing the right to receive 150,000 shares of Terns common stock. The option vests over four years, and the restricted stock unit award vests based on the achievement of milestones stock prices with respect to Terns common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.81%
Tags
none
News
Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer
Rhea-AI Summary
Terns Pharmaceuticals, Inc. announced the appointment of Amy Burroughs as chief executive officer and her addition to the board of directors. Burroughs brings over 25 years of leadership experience, having led therapeutics and commercial strategies at various companies. Her appointment is aimed at advancing Terns' programs to later stage development and partnership, particularly in oncology and metabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.13%
Tags
management
-
News
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Rhea-AI Summary
Terns Pharmaceuticals, Inc. granted an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended. The award consists of options to purchase 19,000 shares of Terns common stock with a 10-year term and an exercise price per share equal to $5.26. The options vest over four years, subject to the employee’s continued service through the applicable vesting dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Terns Pharmaceuticals, Inc. (TERN) plans to advance its diverse pipeline of programs in oncology and metabolic diseases, with key proof-of-concept readouts for TERN-701 (CML) and TERN-601 (obesity) anticipated in 2H24. The company is prioritizing capital allocation to its oncology and obesity programs, with cash and cash equivalents of $267M expected to provide runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
News
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
Rhea-AI Summary
Terns Pharmaceuticals, Inc. (TERN) announced the granting of an equity inducement award to a new employee under the 2022 Employment Inducement Award Plan. The award consists of options to purchase 19,000 shares of Terns common stock at an exercise price of $6.49 per share, with a 10-year term and vesting over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
none
Stock TERN logo
Terns Pharmaceuticals Inc

Nasdaq:TERN

TERN Rankings

#3406 Ranked by Market Cap
#3703 Ranked by Stock Gains
N/A Ranked by Dividends

TERN Stock Data

332.31M
26.93M
1.86%
111.26%
6.95%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Foster City

About TERN

terns pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver diseases and cancers. the company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in china to advance its growing pipeline of drugs that are optimized against clinically-validated targets. based in san mateo, california and shanghai, terns is focused on bringing forward innovative therapeutic candidates with the potential to address significant unmet medical needs in china and globally.